Progresses in Real-World Research of Secukinumab for the Treatment of Psoriasis in China
This article comprehensively reviews the progress of treating 500,000 psoriasis patients in China since the initiation of the first real-world study on secukinumab for psoriasis in the Hainan Boao Lecheng International Medical Tourism Pilot Zone in 2018,particularly following its approval and market release in China in 2019.Over 30 research teams have conducted real-world studies on secukinumab,providing objective evidence regarding its initial efficacy,sustained efficacy,and adverse reactions in China's psoriasis patients.The results indicate that secukinumab,as an IL-17A-targeting biologic,significantly improves the psoriasis area and severity index and dermatology life quality index,with manageable adverse reactions.Compared with traditional therapies and other biologics,secukinumab exhibits a faster onset,more stable long-term efficacy,and a lower risk of relapse.
万方数据
维普
